Abstract:We previously demonstrated significant therapeutic activities associated with adenoviral vector-mediated Herpes Simplex Virus/thymidine kinase (AdHSV-tk) with ganciclovir (GCV) in situ gene therapy in the RM-1 orthotopic mouse prostate cancer model and interleukin-12 (AdmIL-12) in situ gene therapy in the RM-9 orthotopic mouse prostate model for prostate cancer. In both protocols, local cytotoxicity and activities against pre-established lung metastases were demonstrated. To test whether combined AdHSV-tk+GCV+IL-12 gene therapy would lead to enhanced therapeutic effects when compared to either treatment alone, we used RM-9 mouse prostate cancer cells in both orthotopic and pre-established lung metastases models of prostate cancer. Combined treatment with a single injection of optimal doses of AdHSV-tk+GCV or AdmIL-12 led to significantly increased suppression of orthotopic tumor growth. IL-12 gene therapy alone was more effective than AdHSV-tk+GCV in suppressing spontaneous lymph node metastases and pre-established lung metastases but combination gene therapy did not result in additional anti-metastatic activities. Combination gene therapy also did not achieve significantly better animal survival compared to AdHSV-tk+GCV or AdmIL-12 alone. Analysis of localized antitumor activities demonstrated that AdHSV-tk+GCV therapy induced higher levels of necrosis compared to AdmIL-12 or combination therapy. However, both treatments alone and combination therapy produced similar increases in apoptotic index. To address the possible mechanisms of locally co-operative cytotoxic activities, we analyzed the systemic natural killer (NK) response and the numbers of tumor-infiltrating immune cells using quantitative immunohistochemical analysis. AdHSV-tk+GCV therapy alone led to detectable increases in iNOS-positive cells, CD4+and CD8+T-cells and moderately increased numbers of F4/80 (macrophage selective)-positive cells within treated tumors. In contrast, AdmIL-12 elicited a highly robust pattern of tumor infiltration for all four of these immune cells that was in general mimicked by combination therapy. Further analysis of the accumulation of transforming growth factor-β1 (TGF-β1) immunohistochemical staining demonstrated that AdHSV-tk+GCV treatment, but not AdmIL-12 treatment, produced cancer cell-associated increases in this cytokine relative to control Ad-β-gal injections. Interestingly, local injection with AdHSV-tk+GCV induced significant splenocyte-derived NK cell cytolytic activities with maximal response 7 days following treatment, whereas AdmIL-12 injection produced significantly higher NK activity with maximal response 2 days following injection. The combined treatment produced a higher systemic NK response over the 14-day treatment period. Depletion of NK cells in vivo demonstrated that this immunocyte subpopulation was responsible for early locally cytotoxic activities induced by AdHSV-tk+GCV but not AdmIL-12 and that NK activities were largely responsible for activities against pre-established metastases generated by both gene therapy protocols.

Evaluation of the Effect of HSV-tk/GCV Adenoviral Vector Vaccine Candidate in Inhibiting the Growth of Myeloma Tumors by Inducing Autophagy in BALB/c Mice

The Combinatorial Effect of Ad-IL-24 and Ad-HSV-tk/GCV on Tumor Size, Autophagy, and UPR Mechanisms in Multiple Myeloma Mouse Model

Killing effect of mutant herpes simplex virus type 1 thymidine kinase on rat C6 glioma cells

Gene Therapy with HSV1-sr39TK/GCV Exhibits a Stronger Therapeutic Efficacy Than HSV1-TK/GCV in Rat C6 Glioma Cells

[Advances in Measles Virus for Cancer Therapy].

Radiofrequency Hyperthermia-Enhanced Herpes Simplex Virus-Thymidine Kinase/ganciclovir Direct Intratumoral Gene Therapy of Hepatocellular Carcinoma

Combination Effect of Oncolytic Adenovirus Therapy and Herpes Simplex Virus Thymidine Kinase/ganciclovir in Hepatic Carcinoma Animal Models.

Ex vivo and in vivo adenovirus-mediated gene therapy strategies induce a systemic anti-tumor immune defence in the B16 melanoma model

Molecular Imaging-Monitored Radiofrequency Hyperthermia-Enhanced Intratumoral Herpes Simplex Virus-Thymidine Kinase Gene Therapy for Rat Orthotopic Ovarian Cancer.

Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk

Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy for experimental prostate cancer

Cancer Gene Therapy of Adenovirus-Mediated Anti-4-1bb Scfv in Immunocompetent Mice

Combination gene therapy with adenoviral vector-mediated HSV-tk+GCV and IL-12 in an orthotopic mouse model for prostate cancer

[Experimental Study on Human Pulmonary Adenocarcinoma Cell A549 Transfected with HSV₁-TK Gene in Vitro and in Vivo].

Adenovirus vector-mediated expression of TMEM166 inhibits human cancer cell growth by autophagy and apoptosis in vitro and in vivo.

Oncolytic Myxoma Virus Increases Autophagy in Multiple Myeloma

Augmentation of Antitumor Effect of Adenovirus-Mediated CD Suicide Gene Therapy by Cotransfer of Interleukin 2 Gene in Melanoma-Bearing Mice.

An Oncolytic Adenovirus Expressing Herpes Simplex Virus-Thymidine Kinase for Targeting Cancer Therapy: an in Vitro Evaluation

Enhancement of Cancer Radiation Therapy by Use of Adenovirus-Mediated Secretable Glucose-Regulated Protein 94/gp96 Expression

TK Gene Combined with Mil-2 and Mgm-Csf Genes in Treatment of Gastric Cancer

A New Oncolytic Adenoviral Vector Carrying Dual Tumour Suppressor Genes Shows Potent Anti-Tumour Effect